^
    6d
    EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    10d
    A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P3, N=120, Recruiting, Evopoint Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Epidaza (chidamide) • XNW5004
    12d
    The Synergistic Anti-Leukemia Effect of Bcl-2 Inhibitor Combined with HDAC Inhibitor by PI3K/AKT/FoxO1 Axis in T-Cell Acute Lymphoblastic Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The combination of VEN and CDM exerts synergistic anti-leukemia effects by inhibiting cellular proliferation, inducing G0/G1 phase arrest and promoting apoptosis through PI3K/AKT/FoxO1 axis in T-ALL.
    Journal • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CCNE2 (Cyclin E2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    13d
    Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)
    13d
    Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    temozolomide • irinotecan • Epidaza (chidamide) • Qarziba (dinutuximab beta)
    18d
    Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (clinicaltrials.gov)
    P2, N=100, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial primary completion date
    |
    decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    19d
    Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=101, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide) • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)
    22d
    Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis. (PubMed, Front Immunol)
    In patients with R/R AML, the CACAG-VEN regimen resulted in significant clinical benefits, with a high CRc rate and encouraging survival, as well as being well tolerated. https://www.chictr.org.cn/, identifier, ChiCTR2200065634.
    Clinical • P1 data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    24d
    CM-AML-001: Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML (clinicaltrials.gov)
    P2, N=134, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Epidaza (chidamide)
    1m
    INSR/AKT1 axis promotes cells proliferation and migration in acute myeloid leukemia. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    Additionally, suppressing AKT1 expression diminished the impact of INSR on promoting AML cells proliferation, invasion, and migration. This study indicates that INSR expression is elevated in AML cells after treating with chidamide and that INSR promotes AML cells proliferation and migration by upregulating AKT1 expression.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • IR (Insulin receptor)
    |
    Epidaza (chidamide)
    1m
    Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. (PubMed, Trials)
    This study aims to demonstrate that ABC-14 regimen is non-inferior to "3 + 7" regimen in newly diagnosed AML induction therapy while overcoming AB resistance and reducing toxicity associated with "3 + 7". It seeks to provide a broadly applicable alternative induction strategy for AML.
    Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • MCL1 (Myeloid cell leukemia 1)
    |
    TP53 mutation • FLT3-ITD mutation
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    2ms
    PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Terminated, Henan Cancer Hospital | Phase classification: P1/2 --> P1 | Trial completion date: Feb 2025 --> Aug 2025
    Phase classification • Trial completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    Epidaza (chidamide) • parsaclisib (INCB50465)